The ASCO roundup: ArQule drug flunks a mid-stage test

Plenty of more early-stage and mid-stage study results came to light at ASCO over the past day. Here are some of the highlights: ArQule said that its lung cancer drug flunked a mid-stage study, but it flagged some positive results for a subset of patients taking the therapy. About two thirds of the patients taking a combination of ARQ-197 and Tarceva demonstrated an improvement in survival rates, but that wasn't enough to give it a significant statistical edge over Tarceva alone. Patients...

GTx shares dive after toremifene flunks PhIII cancer trial

GTx (NASDAQ:  GTXI) ‎reported yesterday afternoon that its prostate cancer prevention drug failed to perform significantly better than a placebo in a late-stage trial, and the news pushed its stock price into a 37 percent dive as one analyst announced that the data signalled "game over" for the cancer indication. Patients taking toremifene 20 mg had a 10.2 percent lower rate of prostate cancer than the control group, but that wasn't enough to achieve statistical significance....